Related Experiment Video
Updated: Feb 17, 2026
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
Published on: March 17, 2014
Extracellular Particles Derived From Mesenchymal Stromal Cells Reduce Pseudomonas aeruginosa Lung Infection and
Sharanya Sarkar1, Roxanna Barnaby1, Zachary Faber2
1Department of Microbiology and Immunology Geisel School of Medicine at Dartmouth Hanover New Hampshire USA.
Abstract:
The World Health Organization and the U.S. Centre for Disease Control and Prevention have reported that antibiotic-resistant infections with Pseudomonas aeruginosa present a significant health risk worldwide. In the genetic disease cystic fibrosis (CF), chronic antibiotic-resistant Pseudomonas lung infections and persistent inflammation remain the leading causes of mortality. While highly effective modulator therapy (HEMT) dramatically improves lung function in CF, they fail to eradicate chronic infections or eliminate the associated hyperinflammatory state. Thus, there is an urgent need for innovative therapies that can simultaneously eliminate antibiotic-resistant P. aeruginosa lung infection and the attendant hyperinflammatory lung environment. Mesenchymal stromal cell-derived extracellular particles (MSC EPs) represent a promising solution, offering potent anti-inflammatory and antimicrobial properties while being safe and non-toxic. This study demonstrates, using a CF mouse model of infection, that MSC EPs reduce acute P. aeruginosa lung infection and inflammation. As the first investigation of MSC EPs in CF mice, this research underscores the dual effects of MSC EPs; reducing inflammation and bacterial burden. These findings mark an important advancement in antimicrobial therapy, addressing the unmet need for reducing antibiotic-resistant infections and hyperinflammation in CF as well as other diseases with chronic, antibiotic-resistant P. aeruginosa infections.
Insights
Mesenchymal stromal cell-derived extracellular particles (MSC EPs) effectively reduce lung inflammation and bacterial burden in cystic fibrosis (CF) mouse models. This offers a novel therapeutic approach for antibiotic-resistant Pseudomonas aeruginosa infections and hyperinflammation in CF.
Area of Science:
- Pulmonary Medicine
- Microbiology
- Regenerative Medicine
Background:
- Antibiotic-resistant Pseudomonas aeruginosa infections pose a global health threat, particularly in cystic fibrosis (CF).
- Chronic P. aeruginosa lung infections and inflammation are leading causes of mortality in CF patients.
- Current therapies, including highly effective modulator therapy (HEMT), do not eradicate chronic infections or resolve hyperinflammation in CF.
Purpose of the Study:
- To investigate the efficacy of mesenchymal stromal cell-derived extracellular particles (MSC EPs) in treating P. aeruginosa lung infections and inflammation in a CF mouse model.
- To assess the potential of MSC EPs as a dual-action therapy for reducing both bacterial burden and hyperinflammation.
Main Methods:
- A cystic fibrosis mouse model was utilized to simulate chronic lung infections.
- Mesenchymal stromal cell-derived extracellular particles (MSC EPs) were administered to assess their therapeutic effects.
- Lung inflammation and bacterial load were measured to evaluate treatment outcomes.
Main Results:
- MSC EPs demonstrated a significant reduction in acute P. aeruginosa lung infection.
- MSC EPs effectively reduced inflammation in the lungs of CF mice.
- This study is the first to show the dual anti-inflammatory and antimicrobial effects of MSC EPs in a CF mouse model.
Conclusions:
- MSC EPs show promise as a novel therapeutic strategy for managing antibiotic-resistant P. aeruginosa infections in CF.
- The dual action of MSC EPs in reducing both infection and inflammation addresses a critical unmet need in CF treatment.
- Further research into MSC EPs could lead to advancements in treating chronic P. aeruginosa infections beyond CF.
